Jakarta, July 31, 2025 – Based on the Consolidated Financial Statements of PT Enseval Putera Megatrading Tbk and Its Subsidiaries (the “Company”) as of June 30, 2025, and for the period then ended (Unaudited), the Company hereby announces that in the first half of 2025, its Net Sales amounted to IDR 16,056.77 billion, representing a 2.87% increase compared to Net Sales in the first half of 2024, which were recorded at IDR 15,609.29 billion.

The Company’s Cost of Goods Sold in the first half of 2025 amounted to IDR 14,443.52 billion, an increase of 2.55% compared to the first half of 2024, which was recorded at IDR 14,084.71 billion.

Accordingly, the Company recorded a Gross Profit of IDR 1,613.25 billion in the first half of 2025, growing by 5.82% compared to the Gross Profit in the first half of 2024, which was IDR 1,524.59 billion.

In the first half of 2025, the Company’s Operating Expenses amounted to IDR 1,115.76 billion, consisting of Selling Expenses of IDR 971.91 billion and General and Administrative Expenses of IDR 143.84 billion, representing a 6.65% increase compared to the first half of 2024. As a result, the Company recorded an Operating Profit of IDR 497.50 billion, an increase of 4.00% compared to the Operating Profit in the first half of 2024, which was IDR 478.37 billion.

The Company’s Profit Before Income Tax Expenses in the first half of 2025 amounted to IDR 506.98 billion, up by 7.06% compared to the same period in 2024. The composition of Other Income (Expenses) includes Financial Income of IDR 6.20 billion, Financial Expenses of IDR 11.26 billion, Final Tax Expenses of IDR 1.79 billion, Share in Net Profit of Associates of IDR 3.94 billion, Other Operating Income of IDR 16.11 billion, and Other Operating Expenses of IDR 3.70 billion.

The Company’s Income Tax Expense in the first half of 2025 was IDR 114.04 billion, an increase of 5.70% compared to the same period in 2024, which was IDR 107.88 billion.

As a result, the Company recorded a Profit for the Period of IDR 392.94 billion in the first half of 2025, an increase of 7.46% compared to the same period in 2024, which was recorded at IDR 365.68 billion.

Comparing the Company’s Consolidated Statement of Financial Position as of June 30, 2025 (Unaudited), to that of December 31, 2024 (Audited), the Company’s Total Assets increased by 6.54%, from IDR 11.49 trillion to IDR 12.24 trillion. Total Liabilities increased by 21.57%, from IDR 3.91 trillion as of December 31, 2024, to IDR 4.75 trillion in the first half of 2025. Accordingly, Total Equity slightly decreased by 1.22%, from IDR 7.58 trillion to IDR 7.49 trillion in the first half of 2025.

Performance of Each Division
The Company currently has 7 divisions, consisting of the Consumer Goods Division, Prescription Drugs Division, Over-the-Counter Drugs Division, Raw Materials for Sale Division, Medical Devices Division, Veterinary Medicine and Livestock Division, and Healthcare and Transportation Services Division.

The performance of each division within the Company is detailed as follows:

• Consumer Goods Division contributed the largest portion to total Net Sales, amounting to 37.85%. In the first half of 2025, this division recorded Net Sales of IDR 6,076.73 billion, a decrease of 2.00% compared to the same period in 2024.

• Prescription Drugs Division contributed the second-largest share with 34.52%. Up to the first half of 2025, this division recorded Net Sales of IDR 5,542.67 billion, an increase of 6.85% compared to the same period in 2024.

• Over-the-Counter Drugs Division recorded Net Sales of IDR 2,380.67 billion in the first half of 2025, contributing 14.83% and growing by 5.72% compared to the same period in 2024.

• Raw Materials Division recorded Net Sales of IDR 1,228.21 billion in the first half of 2025, an increase of 4.15% compared to the same period in 2024, contributing 7.65%.

• Medical Devices Division contributed 4.73% in the first half of 2025, with Net Sales of IDR 759.81 billion, up by 4.20% compared to the same period in 2024.

• Veterinary Medicine and Livestock Division recorded Net Sales of IDR 27.83 billion, up 5.18% compared to the same period in 2024, which was IDR 26.46 billion. This division contributed 0.17% to the Company’s total Net Sales.

• Healthcare and Transportation Services Division recorded Net Sales of IDR 40.85 billion, growing 18.58% compared to the same period in 2024. This division contributed 0.25%.

About Enseval
Enseval is the largest distribution company in Indonesia, having commenced its distribution activities since 1973 and now employing more than 5,000 people. Enseval became a public company on August 1, 1994, under the name PT Enseval Putera Megatrading Tbk (IDX: EPMT). In addition to distributing products from the Kalbe Group, Enseval is also trusted by other principals, both domestic and international. The Company has an extensive distribution network with 3 Distribution Centers located in Jakarta, Cikarang, and Surabaya, and 48 branches spread across the Indonesian archipelago, as well as 24 branches operated through its Subsidiary, PT Tri Sapta Jaya. To date, the Company has 9 subsidiaries operating in the fields of distribution and logistics, raw materials, medical equipment, healthcare services, and transportation.